WEBVTT 00:00:00.000 --> 00:00:02.600 Welcome back to the deep dive, the place where 00:00:02.600 --> 00:00:05.320 we take that fire hose of information, all the 00:00:05.320 --> 00:00:07.559 articles, the financials, the deep research, 00:00:07.740 --> 00:00:10.980 and really try to distill it down to the essential, 00:00:11.160 --> 00:00:13.519 the surprising and, you know, the truly memorable 00:00:13.519 --> 00:00:16.379 insights you need to know. And today we are tackling 00:00:16.379 --> 00:00:20.429 a massive subject. I mean, a true. global giant 00:00:20.429 --> 00:00:23.710 a giant whose products are and this is no exaggeration 00:00:23.710 --> 00:00:27.370 in nearly every hospital every research lab and 00:00:27.370 --> 00:00:29.129 clinic around the world we are talking about 00:00:29.129 --> 00:00:32.450 beckton dickinson and company or as pretty much 00:00:32.450 --> 00:00:35.450 everyone knows them just bd exactly and our listener 00:00:35.450 --> 00:00:37.429 provided us with this fascinating stack of sources 00:00:37.429 --> 00:00:40.049 really detailing bd's what century plus history 00:00:40.049 --> 00:00:42.710 a century plus yeah and it's almost incomprehensible 00:00:42.710 --> 00:00:45.649 financial scale and critically the really complex 00:00:45.649 --> 00:00:48.369 and often controversial track record that just 00:00:48.369 --> 00:00:50.429 comes with operating at that level. So our mission 00:00:50.429 --> 00:00:52.590 today isn't just to list off the things they 00:00:52.590 --> 00:00:54.689 make. We want to move beyond the simple product, 00:00:54.869 --> 00:00:56.590 you know, beyond the syringe or the basic lab 00:00:56.590 --> 00:01:00.250 tube and understand the sheer overwhelming scale 00:01:00.250 --> 00:01:03.649 of this American multinational medical technology 00:01:03.649 --> 00:01:06.930 powerhouse. This is a company that is, I mean, 00:01:06.950 --> 00:01:09.370 it's foundational to our global health care infrastructure. 00:01:09.629 --> 00:01:11.810 And that infrastructure is enormous. You see, 00:01:11.890 --> 00:01:14.849 BD isn't just. a device manufacturer anymore. 00:01:15.010 --> 00:01:18.489 They are a, well, a sophisticated provider of 00:01:18.489 --> 00:01:20.290 systems. What does that mean exactly? A provider 00:01:20.290 --> 00:01:22.530 of systems? It means they're producing the big 00:01:22.530 --> 00:01:24.969 instrument systems. They're providing the specific 00:01:24.969 --> 00:01:28.569 differentiated chemical regions you need to run 00:01:28.569 --> 00:01:30.489 those systems. The consumables. The consumables, 00:01:30.549 --> 00:01:32.370 exactly. And now they're branching heavily into 00:01:32.370 --> 00:01:36.030 these high -value... consulting and analytics 00:01:36.030 --> 00:01:38.609 services, they are selling the entire operating 00:01:38.609 --> 00:01:40.810 solution, not just the hardware. Okay. So to 00:01:40.810 --> 00:01:42.530 give everyone a quick scale check, and this is 00:01:42.530 --> 00:01:44.310 really important because it anchors our later 00:01:44.310 --> 00:01:46.969 discussion on corporate responsibility. BD was 00:01:46.969 --> 00:01:50.689 founded way, way back in 1897 in New York City, 00:01:50.810 --> 00:01:53.670 later moved its headquarters to Franklin Lakes, 00:01:53.790 --> 00:01:56.269 New Jersey. Right. But let's look at their modern 00:01:56.269 --> 00:01:58.489 financial footprint. The numbers we have are 00:01:58.489 --> 00:02:01.670 based on the fiscal year 2025 updates. And the 00:02:01.670 --> 00:02:04.530 revenue figure alone is just staggering. They're 00:02:04.530 --> 00:02:07.730 reporting, what, U .S. $21 .8 billion in annual 00:02:07.730 --> 00:02:10.250 revenue? $21 .8 billion. And to put that into 00:02:10.250 --> 00:02:12.870 perspective for you, that figure is more than 00:02:12.870 --> 00:02:15.229 the annual GDP of some small nations. It's a 00:02:15.229 --> 00:02:17.569 colossal amount of money. And that, what, nearly 00:02:17.569 --> 00:02:20.909 $22 billion in revenue sits on top of U .S. $55 00:02:20.909 --> 00:02:24.930 .3 billion in total assets? $55 .3 billion. I 00:02:24.930 --> 00:02:26.830 mean, this is not a company that can afford to 00:02:26.830 --> 00:02:29.569 fail. It's an integrated, systemic giant. It 00:02:29.569 --> 00:02:33.240 employs 72... And they're a key component of 00:02:33.240 --> 00:02:37.319 the S &P 500, traded as NYSE, BDX. They're ranked 00:02:37.319 --> 00:02:40.340 high on the 2024 Fortune 500 list, coming in 00:02:40.340 --> 00:02:42.879 at number 211. Right, based on their 2023 performance. 00:02:43.319 --> 00:02:45.759 The sheer magnitude of their business means every 00:02:45.759 --> 00:02:47.759 single decision they made from a tiny manufacturing 00:02:47.759 --> 00:02:50.639 change to a huge legal settlement has global 00:02:50.639 --> 00:02:52.960 implications. So what we are really teasing out 00:02:52.960 --> 00:02:55.300 today is the central tension. It's the contract 00:02:55.300 --> 00:02:58.360 between that long, stable history and their extremely 00:02:58.360 --> 00:03:01.620 aggressive modern growth. A strategy built on 00:03:01.620 --> 00:03:04.740 these mega acquisitions. Exactly. And the significant 00:03:04.740 --> 00:03:07.479 safety, legal and ethical challenges that have 00:03:07.479 --> 00:03:09.539 repeatedly come along with that explosive growth. 00:03:09.659 --> 00:03:12.180 It's really the story of a necessary provider 00:03:12.180 --> 00:03:14.780 whose quest for dominance has often put it into 00:03:14.780 --> 00:03:18.500 conflict with regulators and competitors. You've 00:03:18.500 --> 00:03:20.719 hit it right there. We're looking at a critical 00:03:20.719 --> 00:03:23.340 piece of health care that is, at the same time, 00:03:23.400 --> 00:03:26.020 managing world -leading green initiatives and 00:03:26.020 --> 00:03:28.560 also high -stakes safety recalls. So let's start 00:03:28.560 --> 00:03:31.560 right where the money and the power truly began 00:03:31.560 --> 00:03:35.659 to diverge from that original 1897 vision. Let's 00:03:35.659 --> 00:03:37.840 get into Section 1 then. The Foundation and the 00:03:37.840 --> 00:03:40.650 Financial Engines of Growth. You mentioned the 00:03:40.650 --> 00:03:43.490 1897 founding by Maxwell Becton and Fairleigh 00:03:43.490 --> 00:03:45.849 S. Dickinson, which, you know, established them 00:03:45.849 --> 00:03:48.449 as a reliable medical supplier. A very reliable 00:03:48.449 --> 00:03:50.870 supplier, yes. But the BDD we're analyzing today 00:03:50.870 --> 00:03:52.810 is really a creature of the 21st century. It's 00:03:52.810 --> 00:03:54.789 a product of its aggressive merger and acquisition 00:03:54.789 --> 00:03:56.810 strategies. That's absolutely right. The early 00:03:56.810 --> 00:03:59.430 history provides the foundation, but the BD of 00:03:59.430 --> 00:04:02.430 today, this multi -billion dollar entity, is 00:04:02.430 --> 00:04:04.650 primarily the result of what you so aptly called 00:04:04.650 --> 00:04:07.270 the acquisition as expansion strategy. They've 00:04:07.270 --> 00:04:10.250 used capital to just absorb entire technologies, 00:04:10.409 --> 00:04:13.409 to eliminate major competitors and to instantly 00:04:13.409 --> 00:04:16.430 gain market leverage rather than, you know, relying 00:04:16.430 --> 00:04:19.410 on slow organic growth. And we can trace this 00:04:19.410 --> 00:04:21.790 with some really key data points from our sources. 00:04:22.069 --> 00:04:25.269 The first major modern era move detailed here 00:04:25.269 --> 00:04:29.110 came in 2014. That's when BD acquired Carefusion. 00:04:29.329 --> 00:04:32.189 And this wasn't a cheap buy in. Not at all. That 00:04:32.189 --> 00:04:36.029 acquisition was valued at a huge U .S. $12 .2 00:04:36.029 --> 00:04:39.610 billion in cash and stock. $12 .2 billion. And 00:04:39.610 --> 00:04:42.350 what did CareFusion specialize in? Their world 00:04:42.350 --> 00:04:44.350 was medication management and patient safety 00:04:44.350 --> 00:04:47.069 technologies. So this acquisition, it immediately 00:04:47.069 --> 00:04:50.050 amplified BD's presence inside the hospital workflow. 00:04:50.310 --> 00:04:53.110 It instantly made BD indispensable in whole new 00:04:53.110 --> 00:04:55.240 areas of the hospital. But as you pointed out 00:04:55.240 --> 00:04:56.839 earlier, that turned out to be just the warm 00:04:56.839 --> 00:04:59.339 -up act. It really was. The defining event, the 00:04:59.339 --> 00:05:01.860 one that truly cemented BD's status as a mega 00:05:01.860 --> 00:05:04.860 power, was the 2017 acquisition of C .R. Bard. 00:05:05.079 --> 00:05:07.379 That is the deal that completely reshaped the 00:05:07.379 --> 00:05:09.519 company's structural DNA. The price tag on C 00:05:09.519 --> 00:05:12.220 .R. Bard was a monumental U .S. $24 billion. 00:05:12.620 --> 00:05:14.959 $24 billion? That's not just buying a company. 00:05:15.300 --> 00:05:18.860 No, that's integrating two massive, complicated 00:05:18.860 --> 00:05:21.100 healthcare operations under one giant umbrella. 00:05:21.519 --> 00:05:24.439 CR Bard became a wholly owned subsidiary, and 00:05:24.439 --> 00:05:26.680 its product lines are now woven throughout BD's 00:05:26.680 --> 00:05:29.240 current three business segments. And the strategy 00:05:29.240 --> 00:05:32.100 is clearly still in play. Just this year, in 00:05:32.100 --> 00:05:35.699 2024, our sources note BD announced another major 00:05:35.699 --> 00:05:38.040 expansion. That's right. They're acquiring Edwards 00:05:38.040 --> 00:05:40.699 Life Sciences' critical care unit. For how much? 00:05:40.879 --> 00:05:44.879 $4 .2 billion. So they are continuously seeking 00:05:44.879 --> 00:05:48.000 out these high -value, specialized units to either 00:05:48.000 --> 00:05:50.680 dominate a niche or fill a crucial gap in their 00:05:50.680 --> 00:05:53.220 portfolio. So if you look at this strategy, this 00:05:53.220 --> 00:05:56.139 spending spree, $12 .2 billion, $24 billion, 00:05:56.259 --> 00:05:59.319 $4 .2 billion, you realize they are playing a 00:05:59.319 --> 00:06:01.879 game of total market control. That's the goal, 00:06:02.000 --> 00:06:04.740 to be the single source for the widest possible 00:06:04.740 --> 00:06:07.519 range of medical needs, from the simplest disposable 00:06:07.519 --> 00:06:10.480 product to the most complex diagnostic machine. 00:06:10.920 --> 00:06:12.939 This is where the financial data tells a truly 00:06:12.939 --> 00:06:15.259 compelling story because it connects that aggressive 00:06:15.259 --> 00:06:17.540 strategy directly to their current financial 00:06:17.540 --> 00:06:19.879 stature. It's a straight line. If we look at 00:06:19.879 --> 00:06:22.040 their annual revenue figures before and after 00:06:22.040 --> 00:06:25.259 that C .R. Bard acquisition, the effect is just 00:06:25.259 --> 00:06:29.459 dramatic. OK, so prior to the 2017 deal, Becton 00:06:29.459 --> 00:06:32.060 Dickinson reported an annual revenue of U .S. 00:06:32.639 --> 00:06:37.259 $12 .093 billion. A respectable massive company 00:06:37.259 --> 00:06:39.860 by any measure. Right, about $12 billion. Then 00:06:39.860 --> 00:06:42.800 the CR bar deal closes and almost instantaneously 00:06:42.800 --> 00:06:46.300 we see that figure just jump. It skyrockets. 00:06:46.459 --> 00:06:50.220 By 2018, BD's revenue had vaulted to nearly $16 00:06:50.220 --> 00:06:53.339 billion. And today, like we said, we're talking 00:06:53.339 --> 00:06:57.500 about $21 .8 billion for fiscal year 2025. That's 00:06:57.500 --> 00:06:59.610 nearly a doubling of revenue in what? Roughly 00:06:59.610 --> 00:07:01.949 eight years. Eight years, yeah. And the steepest 00:07:01.949 --> 00:07:04.050 inflection point is tied directly to those two 00:07:04.050 --> 00:07:06.829 massive acquisitions. It's an undeniable proof 00:07:06.829 --> 00:07:08.990 point that this strategy is built on absorbing 00:07:08.990 --> 00:07:11.589 external growth rather than waiting for internal 00:07:11.589 --> 00:07:14.009 organic expansion. For investors, that model 00:07:14.009 --> 00:07:16.230 is pure speed and market leverage. Absolutely. 00:07:16.449 --> 00:07:18.730 But managing a structure that complex with these 00:07:18.730 --> 00:07:20.990 continuous integration challenges, it requires 00:07:20.990 --> 00:07:23.310 very specific leadership. Our sources highlight 00:07:23.310 --> 00:07:26.089 Tom Pollin, who is the chairman, CEO and president, 00:07:26.209 --> 00:07:28.029 and he works alongside Christopher DeLorifus, 00:07:28.129 --> 00:07:30.500 who's the chief. financial officer. And they 00:07:30.500 --> 00:07:32.980 are tasked with integrating these huge disparate 00:07:32.980 --> 00:07:36.360 entities while maintaining a positive image for 00:07:36.360 --> 00:07:38.819 a market capitalization that has frequently topped 00:07:38.819 --> 00:07:42.000 $60 billion. It sounds like a tightrope walk. 00:07:42.220 --> 00:07:44.420 It is a tightrope walk. You're trying to satisfy 00:07:44.420 --> 00:07:47.019 the investor appetite for growth, which demands 00:07:47.019 --> 00:07:49.500 speed and efficiency, while you're simultaneously 00:07:49.500 --> 00:07:52.779 dealing with the operational nightmare of merging 00:07:52.779 --> 00:07:55.060 supply chains, quality control systems, corporate 00:07:55.060 --> 00:07:57.800 cultures. And often, as we're about to see, that 00:07:57.839 --> 00:08:00.420 tension between speed and control it leads to 00:08:00.420 --> 00:08:02.079 friction a lot of friction and that friction 00:08:02.079 --> 00:08:04.779 often manifests in legal challenges which brings 00:08:04.779 --> 00:08:08.430 us to the famous syringe wars This is such a 00:08:08.430 --> 00:08:10.790 critical anecdote because it tells us that BD's 00:08:10.790 --> 00:08:14.230 pursuit of market dominance wasn't always ethical. 00:08:14.509 --> 00:08:16.689 No, and this was happening even in the early 00:08:16.689 --> 00:08:19.129 2000s, long before they hit that $21 billion 00:08:19.129 --> 00:08:22.329 mark. It's a foundational story about market 00:08:22.329 --> 00:08:24.649 access and safety innovation. So what happened? 00:08:24.889 --> 00:08:28.290 Back in 2004, BD faced some very serious allegations 00:08:28.290 --> 00:08:30.290 from a company called Retractable Technologies, 00:08:30.829 --> 00:08:33.009 a smaller competitor. And what did they make? 00:08:33.210 --> 00:08:35.750 They developed syringes designed to prevent needle 00:08:35.750 --> 00:08:38.639 stick injury. A crucial safety innovation in 00:08:38.639 --> 00:08:40.799 health care, especially for nurses and doctors. 00:08:41.059 --> 00:08:44.299 So Retractable alleged that BD had engaged in, 00:08:44.399 --> 00:08:47.559 what, blatant anti -competitive behavior? That 00:08:47.559 --> 00:08:50.080 was the claim. Essentially, they were accused 00:08:50.080 --> 00:08:52.799 of using their immense market power, their deep 00:08:52.799 --> 00:08:54.840 relationships with hospitals and distributors, 00:08:54.940 --> 00:08:58.519 to prevent or severely restrict the distribution 00:08:58.519 --> 00:09:01.279 of Retractable's safer syringes. To keep a safer 00:09:01.279 --> 00:09:03.580 product off the market. That was the allegation. 00:09:04.009 --> 00:09:07.070 And the outcome? Well, it speaks volumes about 00:09:07.070 --> 00:09:10.149 the evidence. Beattie agreed to pay a U .S. $100 00:09:10.149 --> 00:09:13.049 million settlement to resolve it. $100 million? 00:09:13.429 --> 00:09:15.590 That's not just a cost of doing business. No, 00:09:15.610 --> 00:09:18.009 it's a public admission of the seriousness of 00:09:18.009 --> 00:09:20.710 attempts to stifle innovation, especially innovation 00:09:20.710 --> 00:09:22.879 designed to protect... frontline health care 00:09:22.879 --> 00:09:25.659 workers. I find that detail particularly damning. 00:09:25.679 --> 00:09:27.840 A $100 million settlement that suggests they 00:09:27.840 --> 00:09:29.980 actively tried to keep a safer product out of 00:09:29.980 --> 00:09:32.279 the hands of nurses and doctors. It puts the 00:09:32.279 --> 00:09:34.419 pursuit of profit directly against the imperative 00:09:34.419 --> 00:09:36.899 of public health and worker safety. And the conflicts 00:09:36.899 --> 00:09:39.059 didn't even stop with the settlement. What happened 00:09:39.059 --> 00:09:42.059 next? Once BD was kind of forced to respond to 00:09:42.059 --> 00:09:45.419 this market need for safety syringes, they released 00:09:45.419 --> 00:09:47.799 a retractable needle of their own. And let me 00:09:47.799 --> 00:09:50.019 guess. Retractable Technologies subsequently 00:09:50.019 --> 00:09:53.519 accused BD of patent infringement. It just escalated 00:09:53.519 --> 00:09:55.440 the legal drama. So we have a sequence here. 00:09:55.580 --> 00:09:58.299 Block the competitor's safer product, pay $100 00:09:58.299 --> 00:10:01.559 million to settle, then face accusations that 00:10:01.559 --> 00:10:04.080 your own eventual safety product infringed on 00:10:04.080 --> 00:10:06.500 the competitor's patents. It suggests an almost 00:10:06.500 --> 00:10:09.720 relentless pursuit of eliminating any competitive 00:10:09.720 --> 00:10:12.250 advantage. even if it requires substantial legal 00:10:12.250 --> 00:10:15.450 risk and, you know, huge payouts. And the conflict 00:10:15.450 --> 00:10:18.190 went even deeper, right, into marketing claims. 00:10:18.490 --> 00:10:21.070 It did. The sources noted a claim by Retractable 00:10:21.070 --> 00:10:23.529 that BD was falsely advertising its own brand 00:10:23.529 --> 00:10:25.750 of retractable needle as the world's sharpest 00:10:25.750 --> 00:10:28.590 needle. The world's sharpest needle. That detail 00:10:28.590 --> 00:10:31.269 shows the incredible competitive intensity. It's 00:10:31.269 --> 00:10:33.669 not enough to be safe or effective. They felt 00:10:33.669 --> 00:10:36.450 they had to claim an absolute superior marketing 00:10:36.450 --> 00:10:38.990 position. Which in turn led to allegations of 00:10:38.990 --> 00:10:41.590 false advertising. It just confirms that the 00:10:41.590 --> 00:10:44.210 commercial stakes in this supposedly altruistic 00:10:44.210 --> 00:10:46.929 industry are incredibly, incredibly aggressive. 00:10:47.190 --> 00:10:49.750 So the takeaway from this first section is really 00:10:49.750 --> 00:10:52.909 that the financial powerhouse BD is today fueled 00:10:52.909 --> 00:10:56.250 by what? Over $40 billion worth of major acquisitions 00:10:56.250 --> 00:11:00.149 has this historical precedent for prioritizing 00:11:00.149 --> 00:11:02.669 market control. Even if that means navigating 00:11:02.669 --> 00:11:05.490 multimillion dollar legal settlements and protracted 00:11:05.490 --> 00:11:07.529 battles over the very basics of product safety 00:11:07.529 --> 00:11:10.830 and fair play. This early conduct, it really 00:11:10.830 --> 00:11:13.169 sets the context for the serious compliance issues 00:11:13.169 --> 00:11:15.029 we're going to discuss later. Okay, that financial 00:11:15.029 --> 00:11:18.289 backstory and legal context are crucial. Let's 00:11:18.289 --> 00:11:20.570 move on to section two and really drill down 00:11:20.570 --> 00:11:24.139 into the products themselves. If BD is this global 00:11:24.139 --> 00:11:26.879 giant, how is that $21 billion empire actually 00:11:26.879 --> 00:11:28.659 structured? You mentioned they operate in three 00:11:28.659 --> 00:11:30.899 core business segments. That's right. The empire 00:11:30.899 --> 00:11:33.720 is very logically divided into three primary 00:11:33.720 --> 00:11:35.759 pillars that ensure they touch the patient, the 00:11:35.759 --> 00:11:37.960 diagnostics, and the research workflow. You've 00:11:37.960 --> 00:11:40.919 got BD medical, BD life sciences, and BD interventional. 00:11:40.940 --> 00:11:44.389 So let's start with pillar one, BD medical. This 00:11:44.389 --> 00:11:46.029 is the segment most people would instinctively 00:11:46.029 --> 00:11:48.750 recognize, I think. It covers the ubiquitous, 00:11:48.850 --> 00:11:51.490 high -volume products of immediate patient care. 00:11:51.710 --> 00:11:54.450 Exactly. BD Medical handles the core instruments 00:11:54.450 --> 00:11:57.230 you'd see every single day. They're manufacturing 00:11:57.230 --> 00:11:59.450 and distributing essential medical and surgical 00:11:59.450 --> 00:12:02.669 products like needles, syringes, IV access devices, 00:12:03.029 --> 00:12:05.450 and, of course, the vital disposal units required 00:12:05.450 --> 00:12:08.250 for safe handling. So this is drug delivery, 00:12:08.529 --> 00:12:11.350 vaccination infrastructure, basic sample collection 00:12:11.350 --> 00:12:13.879 all over the world. That's the heart of it. But, 00:12:13.879 --> 00:12:16.139 and this is the crucial nuance that validates 00:12:16.139 --> 00:12:19.019 their huge revenue. Go on. Beattie Medical isn't 00:12:19.019 --> 00:12:21.500 just a manufacturing shop. The sources emphasize 00:12:21.500 --> 00:12:24.039 that this segment also offers high -value consulting 00:12:24.039 --> 00:12:26.799 and analytics services. Now, this is key to their 00:12:26.799 --> 00:12:29.700 modern profitability. It absolutely is. By offering 00:12:29.700 --> 00:12:32.159 consulting, Beattie is leveraging its massive 00:12:32.159 --> 00:12:35.179 proprietary data set on product usage and workflow 00:12:35.179 --> 00:12:37.580 efficiency. They're primarily targeting large 00:12:37.580 --> 00:12:40.779 organizations, hospitals, integrated healthcare 00:12:40.779 --> 00:12:43.730 systems, large provider networks. So what exactly 00:12:43.730 --> 00:12:45.870 are they consulting on? Is it as simple as selling 00:12:45.870 --> 00:12:48.389 advice on where to put the disposal units? Oh, 00:12:48.429 --> 00:12:50.070 it's far more strategic than that. They're selling 00:12:50.070 --> 00:12:52.870 efficiency models, workflow optimization based 00:12:52.870 --> 00:12:55.509 on clinical data, supply chain management strategies. 00:12:56.129 --> 00:12:58.309 Imagine a hospital network spending millions 00:12:58.309 --> 00:13:02.289 and millions annually on BD equipment. BD can 00:13:02.289 --> 00:13:05.070 then sell that network an integrated solution 00:13:05.070 --> 00:13:08.669 that optimizes the usage and reduces waste. Of 00:13:08.669 --> 00:13:11.149 course, using BD's own products more efficiently. 00:13:11.610 --> 00:13:14.649 Ah, so they move from a pure transactional relationship 00:13:14.649 --> 00:13:18.190 to something more embedded. Exactly, an embedded 00:13:18.190 --> 00:13:20.690 partnership. It deepens the dependence on their 00:13:20.690 --> 00:13:23.549 ecosystem and moves them up the value chain toward 00:13:23.549 --> 00:13:25.389 recurring revenue from intellectual services, 00:13:25.470 --> 00:13:27.370 not just physical goods. That makes the shift 00:13:27.370 --> 00:13:29.669 from a simple hardware company to an integrated 00:13:29.669 --> 00:13:33.690 solutions provider very, very clear. Okay, moving 00:13:33.690 --> 00:13:37.379 to pillar two. We find BD Life Sciences. This 00:13:37.379 --> 00:13:39.700 segment feels like a massive leap into the complex, 00:13:39.820 --> 00:13:42.399 cutting -edge side of medicine. It is. This is 00:13:42.399 --> 00:13:44.620 where the high -tech, high -margin revenue streams 00:13:44.620 --> 00:13:48.639 are secured. It's organized into two parts, biosciences 00:13:48.639 --> 00:13:52.519 and integrated diagnostic solutions. And this 00:13:52.519 --> 00:13:56.090 segment covers the entire spectrum. from initial 00:13:56.090 --> 00:13:59.830 sample handling to complex molecular biology. 00:14:00.129 --> 00:14:02.570 Let's expand on the incredible breadth of the 00:14:02.570 --> 00:14:05.250 offerings here because it truly highlights BD's 00:14:05.250 --> 00:14:08.269 scope. It spans from basic sample handling all 00:14:08.269 --> 00:14:10.649 the way to advanced immunological research tools. 00:14:10.909 --> 00:14:13.070 Okay, so starting at the very beginning, they 00:14:13.070 --> 00:14:15.450 provide pre -analytical solutions for sample 00:14:15.450 --> 00:14:18.210 management. Now, this might sound mundane. But 00:14:18.210 --> 00:14:20.409 it's critical. It is the single most important 00:14:20.409 --> 00:14:23.480 step for accurate testing. If the pre -analytical 00:14:23.480 --> 00:14:26.179 stage fails, if the sample is collected or stored 00:14:26.179 --> 00:14:28.340 incorrectly, the most sophisticated lab test 00:14:28.340 --> 00:14:30.519 in the world is worthless. And then we move to 00:14:30.519 --> 00:14:32.460 the incredibly advanced tools. They're deeply 00:14:32.460 --> 00:14:35.220 involved in immunology research, providing sophisticated 00:14:35.220 --> 00:14:38.059 tools like flow cytometry and multiomics instruments. 00:14:38.440 --> 00:14:41.059 This is a critical area. Flow cytometry, for 00:14:41.059 --> 00:14:42.679 those who haven't spent time in a research setting, 00:14:42.799 --> 00:14:45.440 is essentially high -speed analysis and sorting 00:14:45.440 --> 00:14:47.899 of microscopic particles, usually cells. How 00:14:47.899 --> 00:14:50.899 does it work? It uses lasers to measure the characteristics 00:14:50.899 --> 00:14:54.659 of thousands of cells per second. And BD provides 00:14:54.659 --> 00:14:57.720 not only the expensive, sophisticated instrumentation, 00:14:57.740 --> 00:15:00.980 but also the specialized reagents, the chemical 00:15:00.980 --> 00:15:04.240 keys, if you will, required to tag and identify 00:15:04.240 --> 00:15:06.879 those cells. So they own the machine and the 00:15:06.879 --> 00:15:08.960 fuel. That's a great way to put it. And then 00:15:08.960 --> 00:15:11.120 you mentioned multiomics. What exactly is that? 00:15:11.279 --> 00:15:13.720 Multiomics refers to the comprehensive integrated 00:15:13.720 --> 00:15:16.779 study of multiple biological data sets all at 00:15:16.779 --> 00:15:20.259 the same time. the genome, so DNA, the transcriptome, 00:15:20.379 --> 00:15:23.080 which is RNA, the proteome, proteins, and the 00:15:23.080 --> 00:15:25.340 metabolome, which is small molecules. So this 00:15:25.340 --> 00:15:27.580 is the absolute cutting edge of precision medicine 00:15:27.580 --> 00:15:30.139 and discovery research. It is. And by providing 00:15:30.139 --> 00:15:32.720 these tools, BD positions itself at the very 00:15:32.720 --> 00:15:35.240 foundation of all future drug discovery and personalized 00:15:35.240 --> 00:15:37.500 medicine development. And that segment also covers 00:15:37.500 --> 00:15:40.220 core diagnostics, right? Microbiology and molecular 00:15:40.220 --> 00:15:42.940 testing. Exactly. This includes all the tests 00:15:42.940 --> 00:15:44.879 and instruments needed for identifying pathogens. 00:15:45.529 --> 00:15:47.409 which is critical for infectious disease monitoring 00:15:47.409 --> 00:15:49.690 and hospital infection control, and performing 00:15:49.690 --> 00:15:52.029 high -throughput genetic and molecular testing. 00:15:52.379 --> 00:15:54.179 And wrapping up that life sciences portfolio, 00:15:54.600 --> 00:15:57.539 we see the inclusion of lab automation and informatics. 00:15:57.700 --> 00:16:00.220 That speaks directly to the need for speed and 00:16:00.220 --> 00:16:02.919 efficiency in modern centralized labs. Well, 00:16:02.980 --> 00:16:05.299 when you are processing millions of tests a day, 00:16:05.440 --> 00:16:08.500 human handling is just impossible. So BD provides 00:16:08.500 --> 00:16:11.159 systems for automated sample handling and result 00:16:11.159 --> 00:16:13.419 management. That's the informatics part. They're 00:16:13.419 --> 00:16:15.500 designing the digital highways for the data. 00:16:15.700 --> 00:16:17.600 They are. They're building the infrastructure 00:16:17.600 --> 00:16:20.620 that allows these huge volumes of diagnostic 00:16:20.620 --> 00:16:24.840 data to be generated, stored, and analyzed instantly. 00:16:25.100 --> 00:16:28.100 So BD Life Sciences is essentially equipping 00:16:28.100 --> 00:16:31.340 the entire global diagnostic and scientific research 00:16:31.340 --> 00:16:33.860 infrastructure. That's a key driver of that $21 00:16:33.860 --> 00:16:36.299 billion revenue. Finally, let's talk about Pillar 00:16:36.299 --> 00:16:39.340 3, BD Interventional. This segment handles specific 00:16:39.340 --> 00:16:42.480 devices used in specialized procedures and, fascinatingly, 00:16:42.480 --> 00:16:45.000 is responsible for a product line that has become 00:16:45.000 --> 00:16:47.759 a generic term for its category. This is a fun 00:16:47.759 --> 00:16:49.860 example that really speaks volumes about market 00:16:49.860 --> 00:16:52.200 penetration. This segment is responsible for 00:16:52.200 --> 00:16:54.820 the popular plastic conical screw top test tubes, 00:16:54.940 --> 00:16:57.120 the ones every school kid and every Ph .D. knows. 00:16:57.340 --> 00:17:00.200 The Falcon tubes. The Falcon tubes. The classic 00:17:00.200 --> 00:17:03.120 Falcon tube. You cannot walk into a laboratory 00:17:03.120 --> 00:17:05.880 anywhere in the world without seeing one. Precisely. 00:17:06.190 --> 00:17:09.049 The brand name Falcon Tubes is so dominant, so 00:17:09.049 --> 00:17:12.009 ubiquitous, due to the popularity of BD's product 00:17:12.009 --> 00:17:14.750 line, that it's often used as a generic term 00:17:14.750 --> 00:17:17.730 for any conical screw top test tube, regardless 00:17:17.730 --> 00:17:19.650 of the actual manufacturer. It's like saying 00:17:19.650 --> 00:17:23.289 Kleenex instead of tissue. Or Band -Aid. instead 00:17:23.289 --> 00:17:26.730 of adhesive bandage. It means BD's brand is synonymous 00:17:26.730 --> 00:17:29.269 with the basic, fundamental unit of laboratory 00:17:29.269 --> 00:17:31.990 work. So when you put it all together, BD is 00:17:31.990 --> 00:17:34.190 structured to cover the entire patient journey. 00:17:34.609 --> 00:17:36.990 BD Medical handles the immediate care interface 00:17:36.990 --> 00:17:39.730 and efficiency. BD Life Sciences manages the 00:17:39.730 --> 00:17:42.130 analytical engine and future research. And BD 00:17:42.130 --> 00:17:43.930 Interventional covers specialized procedural 00:17:43.930 --> 00:17:46.890 equipment and the basic lab infrastructure. It's 00:17:46.890 --> 00:17:49.269 a beautifully constructed vertical monopoly built 00:17:49.269 --> 00:17:51.329 on acquisitions and pervasive market presence. 00:17:51.630 --> 00:17:55.180 That's scale. is certainly impressive. Now we 00:17:55.180 --> 00:17:57.440 turn to Section 3, the Corporate Responsibility 00:17:57.440 --> 00:18:00.740 Report Card. When a company has this large $21 00:18:00.740 --> 00:18:04.839 billion in revenue, 72 ,000 employees, its impact, 00:18:05.059 --> 00:18:07.519 both positive and negative, is just amplified. 00:18:07.779 --> 00:18:10.799 It is. And we see a truly jarring contradiction 00:18:10.799 --> 00:18:14.599 in BD's track record. The juxtaposition is impossible 00:18:14.599 --> 00:18:18.329 to ignore. How so? Well, on one hand... BD has 00:18:18.329 --> 00:18:20.869 clearly invested heavily in environmental stewardship 00:18:20.869 --> 00:18:23.569 and social performance, often leading the field. 00:18:24.119 --> 00:18:26.400 On the other, they have faced these profound 00:18:26.400 --> 00:18:29.779 legal and safety penalties that directly affected 00:18:29.779 --> 00:18:32.440 workers and patients. Let's look at the positive 00:18:32.440 --> 00:18:34.960 side first, which, as you say, is substantial. 00:18:35.279 --> 00:18:37.480 It is. The sources show they've racked up some 00:18:37.480 --> 00:18:40.240 significant, verifiable environmental achievements 00:18:40.240 --> 00:18:42.980 that point to a genuine commitment at the highest 00:18:42.980 --> 00:18:45.579 level. For example. By 2010, they were ranked 00:18:45.579 --> 00:18:48.960 18th in the EPA Fortune 500 list of green power 00:18:48.960 --> 00:18:51.789 purchasers. 18th. That rank tells you they weren't 00:18:51.789 --> 00:18:53.950 just dabbling in sustainability. Not at all. 00:18:54.069 --> 00:18:56.309 It means they were making massive, measurable 00:18:56.309 --> 00:18:59.089 investments in purchasing renewable or low impact 00:18:59.089 --> 00:19:02.269 energy sources to power their colossal manufacturing 00:19:02.269 --> 00:19:04.970 footprint. That requires serious corporate commitment 00:19:04.970 --> 00:19:07.769 and a lot of capital allocation. And they received 00:19:07.769 --> 00:19:10.789 high marks from external analysts as well. In 00:19:10.789 --> 00:19:13.869 the 2009 Newsweek Green Rankings, which assesses 00:19:13.869 --> 00:19:17.230 the 500 largest American corporations, BD was 00:19:17.230 --> 00:19:20.279 listed among the top 100 overall. They ranked 00:19:20.279 --> 00:19:23.619 83rd based on environmental performance, policies, 00:19:23.859 --> 00:19:26.660 and reputation. And if you narrow the field to 00:19:26.660 --> 00:19:29.519 just their industry, the healthcare sector, they 00:19:29.519 --> 00:19:32.279 placed third. Third in their entire sector. That 00:19:32.279 --> 00:19:34.700 is an extremely strong public signal that they 00:19:34.700 --> 00:19:36.319 were setting the benchmark for environmental 00:19:36.319 --> 00:19:39.000 policies among their direct competitors at that 00:19:39.000 --> 00:19:41.220 time. And it goes further. They were consistently 00:19:41.220 --> 00:19:44.339 recognized in major global indices focused on 00:19:44.339 --> 00:19:47.200 long -term sustainability. They were a component 00:19:47.200 --> 00:19:49.839 of the Dow Jones Sustainability World Index for 00:19:49.839 --> 00:19:52.420 four consecutive years. And the Dow Jones Sustainability 00:19:52.420 --> 00:19:54.960 North America Index for five consecutive years. 00:19:55.140 --> 00:19:57.460 And these inclusions are huge. Being listed on 00:19:57.460 --> 00:20:00.140 these indices requires ongoing, detailed performance 00:20:00.140 --> 00:20:02.960 assessments across environmental, social, and 00:20:02.960 --> 00:20:05.599 governance criteria. It suggests sustainability 00:20:05.599 --> 00:20:08.240 wasn't just a marketing campaign. It was integrated 00:20:08.240 --> 00:20:10.609 into their long -term business model. Speaking 00:20:10.609 --> 00:20:13.170 of long -term business models, the sources highlighted 00:20:13.170 --> 00:20:16.089 their dedication to the concept of shared value. 00:20:16.309 --> 00:20:19.710 Yes, where corporate operations create economic 00:20:19.710 --> 00:20:23.150 value in a way that also creates value for society 00:20:23.150 --> 00:20:25.970 by addressing its needs. And the specific example 00:20:25.970 --> 00:20:28.529 they identified was their development of a needleless 00:20:28.529 --> 00:20:31.910 injection system. Exactly. This innovation, while 00:20:31.910 --> 00:20:35.210 certainly a profit driver for BD Medical, simultaneously 00:20:35.210 --> 00:20:38.069 addresses a critical global health challenge. 00:20:38.619 --> 00:20:41.420 The massive risk of accidental needle stick injuries. 00:20:41.700 --> 00:20:43.920 Especially in resource limited settings where 00:20:43.920 --> 00:20:46.319 cross -contamination risks are high. Right. So 00:20:46.319 --> 00:20:48.240 by reducing injury and disease transmission, 00:20:48.480 --> 00:20:51.240 they create social value alongside their economic 00:20:51.240 --> 00:20:54.299 value. It's a textbook case of creating shared 00:20:54.299 --> 00:20:56.940 value. Now, if that were the full story, Beattie 00:20:56.940 --> 00:20:59.380 would be a model corporate citizen. But now we 00:20:59.380 --> 00:21:01.200 turn the page and look at the health and safety 00:21:01.200 --> 00:21:04.430 failures. The darker side. And the contradiction 00:21:04.430 --> 00:21:07.549 is jarring. It is. A company celebrated for its 00:21:07.549 --> 00:21:10.390 high -minded global green goals, facing serious 00:21:10.390 --> 00:21:12.690 penalties for fundamental operational failures. 00:21:12.930 --> 00:21:15.390 The contrast is truly where this deep dive gets 00:21:15.390 --> 00:21:17.430 critical. You have this high -level commitment 00:21:17.430 --> 00:21:19.950 to saving the planet, but then you look at worker 00:21:19.950 --> 00:21:22.500 welfare. And it's a different story. In April 00:21:22.500 --> 00:21:25.359 2016, the Occupational Safety and Health Administration, 00:21:25.700 --> 00:21:31.099 OSHA fined BDUS $112 ,700 for workplace safety 00:21:31.099 --> 00:21:33.579 violations. And the consequence of those failures 00:21:33.579 --> 00:21:37.460 was immediate and severe. OSHA cited BD for repeat 00:21:37.460 --> 00:21:39.920 and serious violations of health and safety law 00:21:39.920 --> 00:21:42.559 after two separate employees suffered partial 00:21:42.559 --> 00:21:44.779 finger amputations. Just think about that operational 00:21:44.779 --> 00:21:47.519 disconnect. A company that spends billions globally 00:21:47.519 --> 00:21:49.539 on acquisitions and millions on sophisticated 00:21:49.539 --> 00:21:52.299 environmental compliance fails at the most basic 00:21:52.299 --> 00:21:55.259 level of protecting its own workers from catastrophic 00:21:55.259 --> 00:21:58.099 preventable machinery accidents. A fine of over 00:21:58.099 --> 00:22:01.880 $112 ,000 for repeat serious violations leading 00:22:01.880 --> 00:22:04.180 to the loss of a worker's body part. It suggests 00:22:04.180 --> 00:22:06.900 a profound failure in basic operational priorities 00:22:06.900 --> 00:22:09.279 compared to their abstract environmental targets. 00:22:09.559 --> 00:22:11.279 And the penalties only escalate when we look 00:22:11.279 --> 00:22:13.660 at patient safety and marketing integrity. This 00:22:13.660 --> 00:22:16.339 brings us back to C .R. Bard, that massive 2017 00:22:16.339 --> 00:22:19.579 acquisition. What happened there? In 2020, BD 00:22:19.579 --> 00:22:22.420 and its newly acquired subsidiary, C .R. Bard 00:22:22.420 --> 00:22:25.680 Inc., they faced a major penalty. They were fined 00:22:25.680 --> 00:22:31.319 $60 million USD. $60 million? For what? For deceptive 00:22:31.319 --> 00:22:33.359 marketing related to the highly controversial 00:22:33.359 --> 00:22:36.480 transvaginal mesh devices. The core violation 00:22:36.480 --> 00:22:39.400 was a systemic failure to adequately inform patients 00:22:39.400 --> 00:22:42.160 and perhaps even practitioners about the serious 00:22:42.160 --> 00:22:44.920 known health risks associated with these devices. 00:22:45.259 --> 00:22:47.660 The transvaginal mesh litigation was a devastating 00:22:47.660 --> 00:22:49.940 chapter in medical device history. It affected 00:22:49.940 --> 00:22:52.619 countless women globally. It did. And a $60 million 00:22:52.619 --> 00:22:55.420 fine for deceptive marketing implies that information 00:22:55.420 --> 00:22:58.140 about health risks was deliberately minimized 00:22:58.140 --> 00:23:00.660 or withheld. It strikes right at the heart of 00:23:00.660 --> 00:23:02.980 patient trust and the ethical obligations of 00:23:02.980 --> 00:23:05.240 a medical technology supplier. And here's where 00:23:05.240 --> 00:23:07.539 the M &A strategy connects directly to the safety 00:23:07.539 --> 00:23:10.000 narrative. Go on. When DD bought C .R. Bard for 00:23:10.000 --> 00:23:13.779 $24 billion in 2017, they acquired Bard's assets, 00:23:13.980 --> 00:23:16.460 its market share, and its looming legal liabilities 00:23:16.460 --> 00:23:19.259 and ethical baggage. That's right. The 2020 find 00:23:19.259 --> 00:23:21.579 shows that BD absorbed not just revenue streams, 00:23:21.720 --> 00:23:24.099 but also profound systemic problems that the 00:23:24.099 --> 00:23:26.160 prior management had created. So if you look 00:23:26.160 --> 00:23:28.779 at the pattern of the $100 million anti -competitive 00:23:28.779 --> 00:23:33.099 settlement, the $112 ,700 fine for worker amputations, 00:23:33.119 --> 00:23:35.799 and the $60 million fine for deceptive marketing, 00:23:36.039 --> 00:23:38.720 you see a constant high -cost pressure point. 00:23:38.819 --> 00:23:41.140 And it's stemming from issues of control, integrity, 00:23:41.519 --> 00:23:44.640 and prioritizing market leverage over safety. 00:23:44.839 --> 00:23:47.640 It creates a deeply complicated portrait of a 00:23:47.640 --> 00:23:50.700 necessary global entity. That discussion of systemic 00:23:50.700 --> 00:23:53.759 failures leads us directly into Section 4, critical 00:23:53.759 --> 00:23:56.380 product safety incidents and global recalls. 00:23:56.400 --> 00:23:58.720 Given that BD products are physically inserted 00:23:58.720 --> 00:24:01.559 into patients or used in these high -stakes diagnostic 00:24:01.559 --> 00:24:04.559 procedures, the consequence of any manufacturing 00:24:04.559 --> 00:24:07.160 deviation is immediate and potentially catastrophic. 00:24:07.700 --> 00:24:10.480 Absolutely. The need for quality control is relentless. 00:24:10.799 --> 00:24:13.019 Even small percentages of failure can translate 00:24:13.019 --> 00:24:15.359 into massive exposure and danger when you're 00:24:15.359 --> 00:24:18.059 shipping millions of units worldwide. And BD's 00:24:18.059 --> 00:24:19.809 history includes several incidents that highlight 00:24:19.809 --> 00:24:21.930 the fragility of massive scale production and 00:24:21.930 --> 00:24:24.549 global supply chains. Let's start back in 2007 00:24:24.549 --> 00:24:27.509 with the discard it to syringe incident in Poland. 00:24:27.730 --> 00:24:30.450 What was the origin of that failure? So in mid 00:24:30.450 --> 00:24:33.369 2007, hospitals and medical services in Poland 00:24:33.369 --> 00:24:36.759 reported a deeply disturbing discovery. They 00:24:36.759 --> 00:24:39.200 were finding remains of dark dust inside some 00:24:39.200 --> 00:24:41.119 of their sterile syringes from the Discarta 2 00:24:41.119 --> 00:24:43.579 series. Dark dust in a syringe that's meant to 00:24:43.579 --> 00:24:46.420 be sterile? That's terrifying. It is. It introduces 00:24:46.420 --> 00:24:48.980 the risk of injection site reactions, inflammation, 00:24:49.200 --> 00:24:53.240 or infection. The specific series, 0607186 and 00:24:53.240 --> 00:24:55.920 others, were withdrawn immediately. And what 00:24:55.920 --> 00:24:58.619 did BD find when they investigated? When BD conducted 00:24:58.619 --> 00:25:01.299 the necessary recall and testing, they determined 00:25:01.299 --> 00:25:04.420 that sterile particulates were present in a minuscule 00:25:04.420 --> 00:25:08.339 0 .013 % of the recalled products. That sounds 00:25:08.339 --> 00:25:11.039 like a tiny number. It is, but this is the crucial 00:25:11.039 --> 00:25:13.670 context. When you produce millions and millions 00:25:13.670 --> 00:25:16.990 of syringes, 0 .013 % is still a significant 00:25:16.990 --> 00:25:19.150 number of contaminated devices being introduced 00:25:19.150 --> 00:25:21.630 into human bodies. It demands a mass recall. 00:25:21.890 --> 00:25:23.509 Absolutely. It demands halting distribution, 00:25:23.849 --> 00:25:26.150 and it damages trust, all due to a microscopic 00:25:26.150 --> 00:25:28.529 contaminant. And that really sets the stage for 00:25:28.529 --> 00:25:30.569 the next, much larger incident that demonstrated 00:25:30.569 --> 00:25:33.670 the true global reach of BD's supply chain and 00:25:33.670 --> 00:25:35.789 the catastrophic potential of a manufacturing 00:25:35.789 --> 00:25:38.509 error. You're talking about the 2010 Q -site 00:25:38.509 --> 00:25:40.990 lure and fee catheter partial recall. Exactly. 00:25:41.259 --> 00:25:43.579 This was a serious high -stakes event. It was. 00:25:43.680 --> 00:25:46.819 The recall involves specific lots of the BD -Q 00:25:46.819 --> 00:25:50.319 site lure access devices and the BD -Nexiva closed 00:25:50.319 --> 00:25:53.619 fee catheter systems. These are central... to 00:25:53.619 --> 00:25:55.500 administering intravenous fluids and medications. 00:25:55.880 --> 00:25:58.059 And what was the life -threatening risk posed 00:25:58.059 --> 00:26:00.400 by the affected devices? The official recall 00:26:00.400 --> 00:26:02.380 notice stated that due to the device defect, 00:26:02.799 --> 00:26:06.059 patients faced the risk of air embolism or leakage 00:26:06.059 --> 00:26:08.660 of blood in therapy. An air embolism, a bubble 00:26:08.660 --> 00:26:10.759 of air entering the bloodstream. Which can lead 00:26:10.759 --> 00:26:13.359 to serious injury or death. This is not a contamination 00:26:13.359 --> 00:26:15.900 issue. This is a critical functional failure 00:26:15.900 --> 00:26:18.339 of the device itself. And this incident is a 00:26:18.339 --> 00:26:20.640 perfect illustration of how BD scale amplifies 00:26:20.640 --> 00:26:23.579 risk. This wasn't a localized... problem. It 00:26:23.579 --> 00:26:25.920 involved millions of units distributed across 00:26:25.920 --> 00:26:28.579 the globe. The scope was immense, and it speaks 00:26:28.579 --> 00:26:30.660 to the difficulty of managing quality control 00:26:30.660 --> 00:26:33.339 across their massive production lines. What were 00:26:33.339 --> 00:26:36.099 the numbers? The voluntary partial recall affected 00:26:36.099 --> 00:26:40.339 approximately 2 .8 million BD -QSITE units and 00:26:40.339 --> 00:26:44.200 2 .9 million BD -Nexiva units, which themselves 00:26:44.200 --> 00:26:47.400 contained 5 million QSITE devices. And this huge 00:26:47.400 --> 00:26:49.779 volume was distributed where? Everywhere. The 00:26:49.779 --> 00:26:53.299 U .S., Canada, Europe. Mexico, South America, 00:26:53.519 --> 00:26:56.539 Asia, the Middle East, South Africa. It was a 00:26:56.539 --> 00:27:00.359 true global health scare. Nearly 6 million potentially 00:27:00.359 --> 00:27:03.180 fatal pieces of equipment requiring immediate 00:27:03.180 --> 00:27:05.460 identification and retrieval across multiple 00:27:05.460 --> 00:27:08.480 continents. What did BD cite as the mechanical 00:27:08.480 --> 00:27:11.420 failure here? BD traced the failure back to a 00:27:11.420 --> 00:27:14.460 manufacturing deviation. They initiated the recall 00:27:14.460 --> 00:27:16.339 after receiving complaints about error entry 00:27:16.339 --> 00:27:18.160 through a specific part of the device. But did 00:27:18.160 --> 00:27:20.019 they fix it? They claim to have corrected the 00:27:20.019 --> 00:27:21.880 deviation, but the incident demonstrated how 00:27:21.880 --> 00:27:23.799 quickly a localized production error can become 00:27:23.799 --> 00:27:25.900 a global crisis when you are the world's leading 00:27:25.900 --> 00:27:28.450 supplier of these products. It showed their ability 00:27:28.450 --> 00:27:30.630 to manage the logistics of a massive recall, 00:27:30.809 --> 00:27:33.289 but it simultaneously exposed the fragility of 00:27:33.289 --> 00:27:35.549 their manufacturing processes. And if the 2010 00:27:35.549 --> 00:27:37.589 event revealed manufacturing vulnerabilities, 00:27:38.029 --> 00:27:40.730 the 2021 recall revealed something perhaps even 00:27:40.730 --> 00:27:43.369 more disturbing. A profound vulnerability in 00:27:43.369 --> 00:27:45.609 supply chain integrity that was deliberate and 00:27:45.609 --> 00:27:49.650 long -term. That's the 2021 IV giving sets recall. 00:27:49.930 --> 00:27:52.450 Right. And this was not a defect that originated 00:27:52.450 --> 00:27:55.480 on BD's assembly line. It was triggered by the 00:27:55.480 --> 00:27:58.920 discovery that a key supplier had actively falsified 00:27:58.920 --> 00:28:01.880 sterilization documents. Falsified them. Falsified 00:28:01.880 --> 00:28:05.460 them. And this egregious deception had gone undetected 00:28:05.460 --> 00:28:09.039 for a staggering 10 years. 10 years of false 00:28:09.039 --> 00:28:11.480 assurances regarding sterility for devices used 00:28:11.480 --> 00:28:14.279 in critical care settings. That means countless 00:28:14.279 --> 00:28:17.619 infusion sets, which must be pristine, were processed 00:28:17.619 --> 00:28:19.640 under questionable standards. And the recall 00:28:19.640 --> 00:28:22.259 affected a wide swath of products essential to 00:28:22.259 --> 00:28:24.950 critical care delivery. Infusion sets for various 00:28:24.950 --> 00:28:27.490 Alaris pumps, standard gravity infusion sets, 00:28:27.750 --> 00:28:30.069 general connectors. These are the tools that 00:28:30.069 --> 00:28:32.789 deliver life -saving IV fluids and vital medications 00:28:32.789 --> 00:28:35.170 to the most vulnerable patients. The reliance 00:28:35.170 --> 00:28:37.549 on a third -party supplier for something as fundamental 00:28:37.549 --> 00:28:40.490 as sterilization introduces a systemic risk that 00:28:40.490 --> 00:28:43.069 BD, as the final name on the product, ultimately 00:28:43.069 --> 00:28:45.630 bears the consequences of. It makes you question 00:28:45.630 --> 00:28:48.450 the robustness of the auditing processes. When 00:28:48.450 --> 00:28:50.849 a decade -long fraud can slip through the cracks 00:28:50.849 --> 00:28:54.059 of a $21 billion enterprise. These three incidents, 00:28:54.420 --> 00:28:57.160 the dark dust particulates, the manufacturing 00:28:57.160 --> 00:28:59.819 flaw causing embolism risk, and the decade of 00:28:59.819 --> 00:29:02.480 sterilization fraud, they provide the sobering 00:29:02.480 --> 00:29:04.980 counterpoint to the positive social and environmental 00:29:04.980 --> 00:29:07.680 achievements. It's a recurring pattern of high 00:29:07.680 --> 00:29:10.240 -level, high -impact risk management failures 00:29:10.240 --> 00:29:13.059 that accompany their relentless pursuit of scale 00:29:13.059 --> 00:29:15.480 and market dominance. We've reached the end of 00:29:15.480 --> 00:29:17.859 our deep dive into the Becton, Dickinson & Company 00:29:17.859 --> 00:29:20.400 sources. Let's bring this all together with our 00:29:20.400 --> 00:29:23.289 outro, key takeaways, and a final thought. The 00:29:23.289 --> 00:29:25.589 summary review, I think, shows a clear trajectory. 00:29:26.029 --> 00:29:29.109 BD starts as a stable 19th century startup and 00:29:29.109 --> 00:29:32.210 transforms into a $21 billion powerhouse through 00:29:32.210 --> 00:29:34.549 a calculated aggressive acquisition strategy. 00:29:34.809 --> 00:29:36.710 Right. They bought CareFusion. They bought C 00:29:36.710 --> 00:29:39.190 .R. Bard. And now Edwards Life Sciences' critical 00:29:39.190 --> 00:29:41.690 care to ensure total market coverage. And that 00:29:41.690 --> 00:29:44.369 immense power is deployed across three indispensable 00:29:44.369 --> 00:29:47.609 segments. Booty Medical, focusing on efficiency 00:29:47.609 --> 00:29:50.410 and the patient interface. BD Life Sciences, 00:29:50.690 --> 00:29:53.150 which owns that entire continuing... from sample 00:29:53.150 --> 00:29:55.809 management to the high -stakes world of multiomics 00:29:55.809 --> 00:29:58.650 research and diagnostics. And Beattie Interventional, 00:29:58.809 --> 00:30:00.809 which handles specialized equipment and even 00:30:00.809 --> 00:30:03.130 gives us that genericized household name, the 00:30:03.130 --> 00:30:06.359 Falcon Tube. But the central tension, the juxtaposition, 00:30:06.359 --> 00:30:09.700 is inescapable. This is a company that is demonstrably 00:30:09.700 --> 00:30:12.140 recognized globally for its environmental excellence. 00:30:12.539 --> 00:30:15.119 Ranking high in EPA lists and sustainability 00:30:15.119 --> 00:30:18.299 indices, praise for creating genuine shared value 00:30:18.299 --> 00:30:21.420 through innovations like the needleless injection 00:30:21.420 --> 00:30:24.519 system. Yet this same necessary global leader 00:30:24.519 --> 00:30:27.180 is constantly burdened by enormous financial 00:30:27.180 --> 00:30:30.200 penalties for profound failures in ethical conduct 00:30:30.200 --> 00:30:33.460 and safety assurance. The $100 million anti -competitive 00:30:33.480 --> 00:30:35.779 settlement aimed at suppressing a safer product. 00:30:36.190 --> 00:30:40.089 The $112 ,700 fine for worker amputations due 00:30:40.089 --> 00:30:42.470 to repeat workplace safety violations. And the 00:30:42.470 --> 00:30:45.230 staggering $60 million fine for deceptive marketing 00:30:45.230 --> 00:30:47.849 related to serious patient health risks concerning 00:30:47.849 --> 00:30:50.869 surgical mesh devices. On top of that, they must 00:30:50.869 --> 00:30:53.569 consistently manage these global crises involving 00:30:53.569 --> 00:30:55.690 millions of units, whether it's a manufacturing 00:30:55.690 --> 00:30:58.930 deviation causing the risk of air embolisms or 00:30:58.930 --> 00:31:01.190 dealing with the fallout from a decade -long 00:31:01.190 --> 00:31:03.990 systemic falsification of sterilization documents 00:31:03.990 --> 00:31:07.019 by a key supplier. chain partner. And this complexity 00:31:07.019 --> 00:31:09.839 is why understanding BD matters to you, the listener. 00:31:10.000 --> 00:31:12.740 This is the unseen foundation of modern medicine. 00:31:12.980 --> 00:31:15.559 Every diagnostic test, every vaccine administered, 00:31:15.859 --> 00:31:18.279 every hospital supply chain is likely touched 00:31:18.279 --> 00:31:20.559 by this company. So understanding them means 00:31:20.559 --> 00:31:22.420 acknowledging the high stakes and the complex, 00:31:22.680 --> 00:31:26.380 often conflicting risk profile inherent in running 00:31:26.380 --> 00:31:28.559 a medical device company at this scale. And that 00:31:28.559 --> 00:31:30.839 leads us directly to the final provocative thought 00:31:30.839 --> 00:31:33.170 we want to leave you with. Okay. We have firmly 00:31:33.170 --> 00:31:35.950 established BD's immense financial scale, U .S. 00:31:35.970 --> 00:31:39.609 $21 .8 billion in annual revenue and U .S. $55 00:31:39.609 --> 00:31:43.569 .3 billion in total assets. Right. Now hold those 00:31:43.569 --> 00:31:45.690 numbers in your mind. Then reflect on the largest 00:31:45.690 --> 00:31:48.630 penalties we discussed, the $100 million anti 00:31:48.630 --> 00:31:51.009 -competitive settlement and the $60 million fine 00:31:51.009 --> 00:31:53.430 for deceptive marketing. When a corporation has 00:31:53.430 --> 00:31:57.829 $55 .3 billion in total assets, that $100 million 00:31:57.829 --> 00:32:01.390 settlement represents approximately 0 .18 % of 00:32:01.390 --> 00:32:03.349 that total. Less than one fifth of one percent. 00:32:03.509 --> 00:32:06.309 Exactly. So does that level of penalty, which 00:32:06.309 --> 00:32:08.890 sounds absolutely enormous in isolation, truly 00:32:08.890 --> 00:32:11.450 function as a deterrent when it represents such 00:32:11.450 --> 00:32:13.470 a microscopic fraction of the company's financial 00:32:13.470 --> 00:32:16.470 base? Does the sheer scale of global operations 00:32:16.470 --> 00:32:20.369 redefine what a truly punitive or corrective 00:32:20.369 --> 00:32:22.910 fine needs to be to actually affect corporate 00:32:22.910 --> 00:32:25.509 behavior? That proportional analysis is something 00:32:25.509 --> 00:32:28.210 worth mulling over. It suggests that for companies 00:32:28.210 --> 00:32:30.910 of this size, legal and ethical compromises might 00:32:30.910 --> 00:32:38.549 be Thank you for joining us for this deep dive 00:32:38.549 --> 00:32:40.650 into Becton, Dickinson & Company. We'll see you 00:32:40.650 --> 00:32:43.069 next time. Stay curious and keep connecting those 00:32:43.069 --> 00:32:43.329 dots.